{"title":"The humanistic burden of atopic dermatitis in Greece: a cross-sectional study.","authors":"Georgia Kourlaba, Katerina Lioliou, Garyfallia Stefanou, Soultana Koukopoulou, Eirinaios Vamvakousis, Dimitrios Ioannides","doi":"10.4081/dr.2025.10164","DOIUrl":"https://doi.org/10.4081/dr.2025.10164","url":null,"abstract":"<p><p>The purpose of this study was to evaluate the quality of life (QoL) and psychosocial burden in adult Greek patients with atopic dermatitis (AD) using validated tools and to investigate factors that influence AD's humanistic burden. This observational, cross-sectional study was conducted in Greece (January-September 2023) with 150 adult members of the patient association \"EPIDERMIA\", all diagnosed with AD. Data was collected via a structured questionnaire, including socio-demographic details, clinical history, AD severity (using the Patient-Oriented Eczema Measure [POEM]), QoL, sleep disorders, and psychological health. Based on POEM scores, 11% of participants had clear/almost clear skin, 27% had mild eczema, 51% had moderate eczema, and 12% had severe/very severe eczema. AD had a moderate or very/extremely large impact on QoL for 29% and 42% of participants, respectively. Insomnia affected 55%, while 31% had mild anxiety, 23% had moderate/severe anxiety, 10% had moderate depression, and 8% had moderately severe/severe depression. AD severity was associated with reduced QoL and higher rates of insomnia, anxiety, and depression. Our study highlights significant associations between AD severity, QoL, and psychosocial factors, emphasizing the need for comprehensive management strategies.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Successfully maintained complete remission of mycosis fungoides by umbilical cord blood transplantation: a case report and literature review.","authors":"Munenari Itoh, Sayaka Oshima, Hiroto Ishii, Shingo Yano, Akihiko Asahina, Yoshimasa Nobeyama","doi":"10.4081/dr.2025.10222","DOIUrl":"https://doi.org/10.4081/dr.2025.10222","url":null,"abstract":"<p><p>Mycosis fungoides (MF) is a major variant of primary cutaneous T-cell lymphoma (CTCL) characterized by infiltration of neoplastic T cells in the epidermis and dermis. This disease progresses gradually and rarely reaches an advanced stage. Once advanced, MF is nearly impossible to treat due to limited therapeutic options. However, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has recently emerged as a potential treatment. Among hematopoietic stem cell (HSC) sources, umbilical cord blood transplantation (UCBT) offers significant advantages. Despite its potential, there are challenges in applying UCBT to adults, and there are only a few reports on its use for MF. We report a Japanese case of advanced MF maintaining complete remission (CR) with UCBT and review previous cases of CTCL, including MF, treated with UCBT.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wioleta Faruga-Lewicka, Małgorzata Dudek, Wiktoria Staśkiewicz-Bartecka, Marek Kardas
{"title":"Self-esteem, self-perception, and self-image of women with acne vulgaris at different age ranges.","authors":"Wioleta Faruga-Lewicka, Małgorzata Dudek, Wiktoria Staśkiewicz-Bartecka, Marek Kardas","doi":"10.4081/dr.2025.10191","DOIUrl":"https://doi.org/10.4081/dr.2025.10191","url":null,"abstract":"<p><p>Acne vulgaris is a common inflammatory dermatosis and the most common disease affecting the hair and sebaceous unit. It usually localizes to the face and, on average, affects 9.4% of the population. Many patients treated for acne vulgaris experience symptoms of anxiety, depression, and social withdrawal, often accompanied by feelings such as anger. This can be particularly exacerbated when dermatological treatment fails to have the expected effect. Given the significant psychosocial effects of the aforementioned dermatosis, early intervention is crucial. The survey was conducted between September 2023 and July 2024. The participants were patients of a cosmetology and aesthetic medicine clinic located in the city of Katowice, Poland. The Teenagers' Quality of Life Index (T-QoL) and Self-Esteem Scale by M. Rosenberg (RSES) were used to conduct the survey. The study confirmed the significant impact of acne vulgaris on psycho-social aspects in women of different ages. Acne significantly lowers self-esteem and negatively affects the sufferers' perception of themselves and their appearance. The impact was shown to be more severe in a group of women over 27 years of age, who exhibited lower self-esteem compared to the younger group. Women with acne often feel the need to hide skin lesions and pay a lot of attention to their appearance, which can lead to reduced quality of life and emotional disturbances. A significant number of women have disturbed self-esteem and negative beliefs about themselves, which may be related to current beauty canons and social pressure for an unblemished appearance. The study underscores the need for a holistic approach to female patients with acne vulgaris, considering both medical and psychological aspects, in order to effectively treat and improve psychological well-being.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lulwa Alogayel, Sara Alrashid, Renad AlKanaan, Raneem Alnajjar, Ghaida Almarshoud
{"title":"Bilateral nevus of Ota in association with nevus flammeus: a case report.","authors":"Lulwa Alogayel, Sara Alrashid, Renad AlKanaan, Raneem Alnajjar, Ghaida Almarshoud","doi":"10.4081/dr.2025.10289","DOIUrl":"https://doi.org/10.4081/dr.2025.10289","url":null,"abstract":"<p><p>Nevus of Ota and nevus flammeus are distinct congenital pigmentary and vascular anomalies, respectively, with different etiologies and clinical implications. While both conditions can present unilaterally, their bilateral coexistence is rare. We report a 39-year-old Filipino female with a medical history of type 2 diabetes mellitus and dyslipidemia who presented to the dermatology clinic with concerns over a newly appearing benign nevus on the sole of her hand. Incidentally, dermatological examination revealed two significant congenital pigmentary lesions: bilateral nevus of Ota and a widespread port-wine stain. The nevus of Ota manifested as well-defined blue-gray macules and patches symmetrically distributed across her face, involving both nasal nostrils and conjunctiva. The nevus flammeus, a congenital vascular malformation, extended over both arms, the upper back, and the chest, presenting as a well-demarcated reddish-purple discoloration. These lesions had been present since birth, remained asymptomatic, and had never been previously evaluated. No systemic involvement was detected, and laboratory investigations were unremarkable. The diagnosis was made clinically. As the patient was not interested in treating the nevi, no treatment was planned. This case highlights the importance of obtaining a detailed family history in all similar cases to aid in understanding the genetic basis of these conditions and their potential coexistence with other congenital dermal anomalies.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cutting-edge insights: LC-OCT and 5% cyclosporine for early lichen sclerosus treatment.","authors":"Caterina Mariarosaria Giorgio, Vittorio Tancredi, Gaetano Licata, Elvira Moscarella, Giuseppe Argenziano, Elisabetta Fulgione, Graziella Babino, Paolino Franzese, Eugenia Veronica Di Brizzi","doi":"10.4081/dr.2025.10279","DOIUrl":"https://doi.org/10.4081/dr.2025.10279","url":null,"abstract":"<p><p>Dear Editor, Atrophic lichen sclerosus (ALS) is a chronic inflammatory dermatosis with significant morbidity, primarily affecting genital areas. The disease is often misdiagnosed or underdiagnosed, resulting in delayed treatment and progression to atrophic stages and permanent scars. While corticosteroids remain the first-line treatment, their long-term use may lead to adverse effects such as skin atrophy, prompting the need for alternative therapies. Cyclosporine, a calcineurin inhibitor, has shown efficacy in managing immune-mediated skin diseases and is delivered effectively through the Pentravan® vehicle. [...].</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Severe relapse of generalized psoriasis in a young patient with Löfgren syndrome history.","authors":"Ermira Ziçishti, Migena Vargu, Sabina Dedej, Eriselda Kurushi, Valbona Zenelaj, Ermira Vasili","doi":"10.4081/dr.2025.10021","DOIUrl":"https://doi.org/10.4081/dr.2025.10021","url":null,"abstract":"<p><p>Psoriasis and sarcoidosis are two systemic inflammatory diseases characterized by elevated Th1 and Th17 lymphocyte activity and overlapping genetic components. Although psoriasis often accompanies known comorbidities, the simultaneous presence of acute sarcoidosis (Löfgren syndrome) is uncommon. A 23-year-old Caucasian male patient with a history of mild psoriasis without relapse since childhood presented with generalized psoriatic plaques. In May 2020, he experienced symptoms compatible with Löfgren syndrome (LöS), which followed complete resolution after three months of systemic corticosteroid therapy. After one year of treatment with adalimumab, the Psoriasis Area and Severity Index (PASI) decreased from 25.3 to 4.2, while sarcoidosis remained stable. The common pathogenic mechanisms between psoriasis and sarcoidosis warrant further investigation. This case emphasizes the importance of vigilance for respiratory symptoms in psoriasis patients and the potential for psoriasis reoccurrence post-sarcoidosis. Dermatologists need to be aware of these associations, promoting comprehensive management strategies for psoriatic patients with a history of sarcoidosis.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Duanyu Wang, Minghao Tan, Nora Iv, Rattanaricky Ung, Gechhorng Lim, Vahid Say, Sokheng Phal, Pengkhun Nov
{"title":"Mendelian randomization analysis of the causal association between metabolite and skin cancer.","authors":"Duanyu Wang, Minghao Tan, Nora Iv, Rattanaricky Ung, Gechhorng Lim, Vahid Say, Sokheng Phal, Pengkhun Nov","doi":"10.4081/dr.2025.10159","DOIUrl":"https://doi.org/10.4081/dr.2025.10159","url":null,"abstract":"<p><p>Skin cancer (SC) is a significant public health issue, with increasing incidence rates globally. Although environmental factors such as ultraviolet (UV) exposure are recognized risk factors, the impact of metabolites on SC development has not been thoroughly examined. This study seeks to explore the causal association between metabolites and SC risks using a Mendelian randomization (MR) approach. Our analysis revealed a total of 76 metabolites associated with SC risk. Of them, leucine to N-palmitoyl-sphingosine ratio, glycerol to palmitoylcarnitine ratio, oleoyl-linoleoyl-glycerol levels, and hypotaurine-to-taurine ratio were strongly associated with SC. Notably, leucine to N-palmitoyl-sphingosine ratio and glycerol to palmitoylcarnitine ratio were linked to increased risk factors for SC. However, oleoyl-linoleoyl-glycerol levels and hypotaurine-to-taurine ratio served as the protective indicators of SC. This study highlights the potential role of metabolites in skin cancer etiology, suggesting that metabolic factors may serve as important targets for prevention and risk assessment strategies.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Psoriasiform rash possibly induced by oral propranolol in a 12-month-old girl with infantile hemangioma: a case report and literature review.","authors":"Sahar Alruhaimi, Fatimah Alowirdi, Waleed Al-Ajroush","doi":"10.4081/dr.2025.10239","DOIUrl":"https://doi.org/10.4081/dr.2025.10239","url":null,"abstract":"<p><p>Infantile hemangiomas are the most common soft-tissue tumors in children, with propranolol, a non-cardioselective β-blocker, considered the first-line treatment for complicated cases. β-blockers have been reported to be the most common causative agents for drug-induced psoriasis in adults. In the pediatric population, only one previous case exists. We report the case of a 12-month-old girl who developed a psoriasiform rash after starting oral propranolol for infantile hemangiomas on the scalp. The patient had no personal or family history of psoriasis, and the rash appeared one week post-initiation of propranolol, presenting as well-defined erythematous, scaly plaques over the body, including the scalp. Infectious causes were excluded, and the rash was diagnosed as a psoriasiform rash, possibly induced by oral propranolol. The patient was switched to atenolol, which resulted in improvement of the hemangioma and complete resolution of the skin lesions. This case highlights the rare but significant risk of psoriasiform eruptions associated with β-blocker therapy in infants, emphasizing the need for careful recognition and monitoring of this potential adverse effect in pediatric patients treated for infantile hemangiomas.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Claudia Paganini, Edoardo Mortato, Lorenzo Tofani, Alfredo Belcastro, Marina Talamonti, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo
{"title":"Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies.","authors":"Claudia Paganini, Edoardo Mortato, Lorenzo Tofani, Alfredo Belcastro, Marina Talamonti, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo","doi":"10.4081/dr.2025.10193","DOIUrl":"https://doi.org/10.4081/dr.2025.10193","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic inflammatory skin disease often requiring systemic therapies for moderate-to-severe cases. Janus kinase (JAK) inhibitors, including upadacitinib, have emerged as effective options, targeting pro-inflammatory cytokines involved in AD pathogenesis. However, adverse dermatologic reactions, such as rosacea-like eruptions, have been observed, potentially linked to immune pathway modulation. This report describes two patients with severe AD who achieved complete disease clearance with upadacitinib but developed rosacea-like eruptions. Both cases required discontinuation of the drug and treatment with antibiotics, which resolved the symptoms. However, withdrawal led to AD flares in one patient, necessitating the reintroduction of upadacitinib at a reduced dose combined with prophylactic antibiotics. These cases underscore the efficacy of JAK inhibitors while highlighting the challenge of managing adverse effects. Individualized treatment approaches, including dose adjustments and adjunctive therapies, are essential for balancing AD control with tolerability. Further research is needed to optimize the management of these reactions.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Filippo Chersi, Sanja Javor, Rosella Gallo, Elia Sala, Cesare Massone
{"title":"Paradoxical reaction under dupilumab triggered by occasional ketoprofen intake.","authors":"Filippo Chersi, Sanja Javor, Rosella Gallo, Elia Sala, Cesare Massone","doi":"10.4081/dr.2025.10214","DOIUrl":"https://doi.org/10.4081/dr.2025.10214","url":null,"abstract":"<p><p>Dupilumab, a monoclonal antibody targeting the IL-4/13 signaling pathway, effectively treats moderate-to-severe atopic dermatitis (AD). Common side effects include injection site reactions, conjunctivitis, and respiratory infections. We report the case of a 28-year-old woman with severe AD involving the periocular and chin regions, genital areas, arms, and legs (Eczema Area and Severity Index [EASI]: 24, itch Visual Analog Scale [VAS]: 8) who showed significant improvement after initiating dupilumab therapy. However, following ketoprofen intake for headache relief, she developed a lupus-like erythematous maculopapular rash on the periocular and malar regions. Immunological tests (ANA, ENA) and photopatch testing ruled out autoimmune or allergic causes. Dupilumab was stopped, and treatment with oral prednisone and cetirizine led to complete resolution. This case highlights a potential drug interaction between dupilumab and ketoprofen, emphasizing the need for awareness of paradoxical facial erythema reactions in patients undergoing dupilumab therapy.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}